My research focuses on understanding the genetic and molecular mechanisms that underlie the initiation and progression of B-cell non-Hodgkin's lymphomas in order to define clinically-relevant biomarkers.
Genomic Profiling Reveals Spatial Intra-Tumor Heterogeneity in Follicular Lymphoma. Leukemia (2018) 32(5):1258-1263. PMID: 29568095
Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. Nat Cell Biol (2017) 19(9):1093-1104. PMID: 28825697
Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nature Genetics (2016) 48(2):183-8. PMID: 26691987
Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nature Genetics (2014) 46(2):176-81. PMID: 24362818
I have a research interest in B-cell Non-Hodgkin’s lymphoma. Our current focus is on follicular lymphoma, an indolent malignancy that remains incurable and for which the typical clinical course is one where patients relapse on several occasions eventually becoming therapy resistant. Our main research questions are to:
To address these questions, we aim to utilise primary lymphoma samples in combination with cutting-edge tools, in vitro and in vivo approaches.
A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care El-Galaly TC, Gaidzik VI, Gaman MA et al. HemaSphere (2023) 7(7) E842
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma Bewicke-Copley F, Korfi K, Araf S et al. Blood Advances (2023) 7(7) 845-855
IBRAP: integrated benchmarking single-cell RNA-sequencing analytical pipeline Knight CH, Khan F, Patel A et al. Briefings in Bioinformatics (2023) 24(7)
Impact of positron emission tomography - computed tomography status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplantation Eyre TA, Barrington SF, Okosun J et al. Haematologica (2023) 108(7) 785-796
Personalised therapy in follicular lymphoma – is the dial turning? Linton KM, Specht L, Pavlovsky A et al. Hematological Oncology (2023) (7)
Biology of follicular lymphoma: insights and windows of clinical opportunity Perrett M, Edmondson C, Okosun J Hematology (United States) (2022) 2022(7) 688-694
Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma Wendler J, Fox CP, Valk E et al. BMC Cancer (2022) 22(7)
The EHA Research Roadmap: Malignant Lymphoid Diseases Dreyling M, André M, Gökbuget N et al. HemaSphere (2022) 6(7) E726
Thyroid MALT lymphoma: self-harm to gain potential T-cell help Wu F, Watanabe N, Tzioni MM et al. Leukemia (2021) 35(7) 3497-3508
Pathogenesis of follicular lymphoma: genetics to the microenvironment to clinical translation Kumar E, Pickard L, Okosun J British Journal of Haematology (2021) 194(7) 810-821For additional publications, please click here
Clinical Research Fellows/PhD students
Academic Clinical Fellows
I graduated in medicine from the University of Cambridge and subsequently undertook my medical and specialty registrar haematology training in London. My research interests in lymphoma biology was developed during my Kay Kendall funded Clinical Research Fellowship with Professor Jude Fitzgibbon at the Barts Cancer Institute where I investigated the genetic heterogeneity and tumour evolution underlying follicular lymphoma and its progression. I was awarded the Royal College of Pathologists Specialty Research Medal for this work.
I returned to the Barts Cancer Institute as a Clinical Senior Lecturer in 2017 and will also be working with collaborators at the Francis Crick Institute.
2017 to present: Clinical Senior Lecturer
2011-2015: Kay Kendall Clinical Research Fellow, Barts Cancer Institute
2015: PhD, Queen Mary University of London
2011: FRCPath, Royal College of Pathologists
2008: MRCP, Royal College of Physicians
2004: MB BChir, University of Cambridge
2002: BA (Hons) Natural Sciences, University of Cambridge